Skip to main content
Top
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1

Authors: Kewei Zhu, Wanchun Wang

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

(−)-Epigallocatechin-3-gallate (EGCG), the most abundant and active polyphenol in green tea, has been demonstrated to have anticancer effects in a wide variety of human cancer. MicroRNAs (miRNAs) are a class of short noncoding RNAs and play important role in gene regulation and are critically involved in the pathogenesis and progression of human cancer. This study aims to investigate the effects of EGCG on osteosarcoma (OS) cells and elucidate the underlying mechanism. Cellular function assays revealed that EGCG inhibited cell proliferation, induced cell cycle arrest and promoted apoptosis of OS cells in vitro, and also inhibited the growth of transplanted tumors in vivo. By miRNA microarray and RT-qPCR analysis, miR-1 was found to be significantly upregulated in MG-63 and U-2OS treated by EGCG in dose- and time-dependent manners, and miR-1 downregulation by inhibitor mimics attenuated EGCG-induced inhibition on cell growth of OS cells. We also confirmed that miR-1 was also frequently decreased in clinical OS tumor tissues. Moreover, both EGCG and miR-1 mimic inhibited c-MET expression, and combination treatment with EGCG and c-MET inhibitor (crizotinib) had enhanced inhibitory effects on the growth of MG-63 and U-2OS cells. Taken together, these results suggest that EGCG has an anticancer effect on OS cells, at least partially, through regulating miR-1/c-MET interaction.
Appendix
Available only for authorised users
Literature
1.
go back to reference Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–32.CrossRefPubMed Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–32.CrossRefPubMed
2.
3.
go back to reference Chen D, Wan SB, Yang H, Yuan J, Chan TH, Dou QP. Egcg, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem. 2011;53:155–77.CrossRefPubMedPubMedCentral Chen D, Wan SB, Yang H, Yuan J, Chan TH, Dou QP. Egcg, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem. 2011;53:155–77.CrossRefPubMedPubMedCentral
4.
go back to reference Lamoral-Theys D, Pottier L, Dufrasne F, Neve J, Dubois J, Kornienko A, et al. Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr Med Chem. 2010;17:812–25.CrossRefPubMed Lamoral-Theys D, Pottier L, Dufrasne F, Neve J, Dubois J, Kornienko A, et al. Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr Med Chem. 2010;17:812–25.CrossRefPubMed
5.
go back to reference Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal. 2005;7:1630–47.CrossRefPubMed Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal. 2005;7:1630–47.CrossRefPubMed
6.
go back to reference Fujiki H, Suganuma M, Kurusu M, Okabe S, Imayoshi Y, Taniguchi S, et al. New tnf-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with egcg and sulindac or tamoxifen. Mutat Res. 2003;523–524:119–25.CrossRefPubMed Fujiki H, Suganuma M, Kurusu M, Okabe S, Imayoshi Y, Taniguchi S, et al. New tnf-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with egcg and sulindac or tamoxifen. Mutat Res. 2003;523–524:119–25.CrossRefPubMed
7.
go back to reference Suganuma M, Saha A, Fujiki H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2011;102:317–23.CrossRefPubMed Suganuma M, Saha A, Fujiki H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2011;102:317–23.CrossRefPubMed
9.
10.
go back to reference Milenkovic D, Jude B, Morand C. Mirna as molecular target of polyphenols underlying their biological effects. Free Radic Biol Med. 2013;64:40–51.CrossRefPubMed Milenkovic D, Jude B, Morand C. Mirna as molecular target of polyphenols underlying their biological effects. Free Radic Biol Med. 2013;64:40–51.CrossRefPubMed
12.
go back to reference Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, et al. Targeting mirnas involved in cancer stem cell and emt regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat Rev Commentaries Antimicrob Anticancer Chemother. 2010;13:109–18. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, et al. Targeting mirnas involved in cancer stem cell and emt regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat Rev Commentaries Antimicrob Anticancer Chemother. 2010;13:109–18.
13.
go back to reference Zhang J, Chen YL, Ji G, Fang W, Gao Z, Liu Y, et al. Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PLoS One. 2013;8, e64954.CrossRefPubMedPubMedCentral Zhang J, Chen YL, Ji G, Fang W, Gao Z, Liu Y, et al. Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PLoS One. 2013;8, e64954.CrossRefPubMedPubMedCentral
14.
go back to reference Schramm L. Going green: the role of the green tea component egcg in chemoprevention. J Carcinogenesis Mutagen. 2013;4:1000142.CrossRef Schramm L. Going green: the role of the green tea component egcg in chemoprevention. J Carcinogenesis Mutagen. 2013;4:1000142.CrossRef
15.
go back to reference Park JS, Khoi PN, Joo YE, Lee YH, Lang SA, Stoeltzing O, et al. Egcg inhibits recepteur d’origine nantais expression by suppressing egr-1 in gastric cancer cells. Int J Oncol. 2013;42:1120–6.PubMed Park JS, Khoi PN, Joo YE, Lee YH, Lang SA, Stoeltzing O, et al. Egcg inhibits recepteur d’origine nantais expression by suppressing egr-1 in gastric cancer cells. Int J Oncol. 2013;42:1120–6.PubMed
16.
go back to reference Ogawa K, Hara T, Shimizu M, Nagano J, Ohno T, Hoshi M, et al. (−)-epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. Oncol Lett. 2012;4:546–50.PubMedPubMedCentral Ogawa K, Hara T, Shimizu M, Nagano J, Ohno T, Hoshi M, et al. (−)-epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. Oncol Lett. 2012;4:546–50.PubMedPubMedCentral
17.
go back to reference Ma YC, Li C, Gao F, Xu Y, Jiang ZB, Liu JX, et al. Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the egfr signaling pathway. Oncol Rep. 2014;31:1343–9.PubMed Ma YC, Li C, Gao F, Xu Y, Jiang ZB, Liu JX, et al. Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the egfr signaling pathway. Oncol Rep. 2014;31:1343–9.PubMed
18.
go back to reference Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. Epigallocatechin-3-gallate (egcg) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 2013;13:632–7.CrossRefPubMed Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. Epigallocatechin-3-gallate (egcg) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 2013;13:632–7.CrossRefPubMed
19.
go back to reference Trudel D, Labbe DP, Araya-Farias M, Doyen A, Bazinet L, Duchesne T, et al. A two-stage, single-arm, phase ii study of egcg-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013;131:357–61.CrossRefPubMed Trudel D, Labbe DP, Araya-Farias M, Doyen A, Bazinet L, Duchesne T, et al. A two-stage, single-arm, phase ii study of egcg-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013;131:357–61.CrossRefPubMed
20.
go back to reference Hsieh TC, Wu JM. Targeting cwr22rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals egcg, genistein and quercetin. Anticancer Res. 2009;29:4025–32.PubMedPubMedCentral Hsieh TC, Wu JM. Targeting cwr22rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals egcg, genistein and quercetin. Anticancer Res. 2009;29:4025–32.PubMedPubMedCentral
21.
go back to reference Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM, et al. Apoptotic effect of egcg in ht-29 colon cancer cells via ampk signal pathway. Cancer Lett. 2007;247:115–21.CrossRefPubMed Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM, et al. Apoptotic effect of egcg in ht-29 colon cancer cells via ampk signal pathway. Cancer Lett. 2007;247:115–21.CrossRefPubMed
22.
go back to reference Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J, Park OJ. Green tea catechin controls apoptosis in colon cancer cells by attenuation of h2o2-stimulated cox-2 expression via the ampk signaling pathway at low-dose h2o2. Ann N Y Acad Sci. 2009;1171:538–44.CrossRefPubMed Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J, Park OJ. Green tea catechin controls apoptosis in colon cancer cells by attenuation of h2o2-stimulated cox-2 expression via the ampk signaling pathway at low-dose h2o2. Ann N Y Acad Sci. 2009;1171:538–44.CrossRefPubMed
23.
go back to reference Xu L, Zhang Y, Wang H, Zhang G, Ding Y, Zhao L. Tumor suppressor mir-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the mapk and pi3k/akt pathway. J Transl Med. 2014;12:244.CrossRefPubMedPubMedCentral Xu L, Zhang Y, Wang H, Zhang G, Ding Y, Zhao L. Tumor suppressor mir-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the mapk and pi3k/akt pathway. J Transl Med. 2014;12:244.CrossRefPubMedPubMedCentral
24.
go back to reference Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, et al. The functional significance of mir-1 and mir-133a in renal cell carcinoma. Eur J Cancer. 2012;48:827–36.CrossRefPubMed Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, et al. The functional significance of mir-1 and mir-133a in renal cell carcinoma. Eur J Cancer. 2012;48:827–36.CrossRefPubMed
25.
go back to reference Li D, Yang P, Li H, Cheng P, Zhang L, Wei D, et al. Microrna-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci. 2012;91:440–7.CrossRefPubMed Li D, Yang P, Li H, Cheng P, Zhang L, Wei D, et al. Microrna-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci. 2012;91:440–7.CrossRefPubMed
26.
go back to reference Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, et al. The tumour-suppressive function of mir-1 and mir-133a targeting tagln2 in bladder cancer. Br J Cancer. 2011;104:808–18.CrossRefPubMedPubMedCentral Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, et al. The tumour-suppressive function of mir-1 and mir-133a targeting tagln2 in bladder cancer. Br J Cancer. 2011;104:808–18.CrossRefPubMedPubMedCentral
27.
go back to reference Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, et al. Microrna-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 2012;40:3689–703.CrossRefPubMed Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, et al. Microrna-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 2012;40:3689–703.CrossRefPubMed
28.
go back to reference Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, et al. Mirna expression profile in human osteosarcoma: role of mir-1 and mir-133b in proliferation and cell cycle control. Int J Oncol. 2013;42:667–75.PubMed Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, et al. Mirna expression profile in human osteosarcoma: role of mir-1 and mir-133b in proliferation and cell cycle control. Int J Oncol. 2013;42:667–75.PubMed
29.
go back to reference Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O’Keefe RJ, et al. The orally bioavailable met inhibitor pf-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res Off J Am Soc Bone Miner Res. 2011;26:1283–94.CrossRef Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O’Keefe RJ, et al. The orally bioavailable met inhibitor pf-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res Off J Am Soc Bone Miner Res. 2011;26:1283–94.CrossRef
30.
go back to reference Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. Mir-1 downregulation cooperates with macc1 in promoting met overexpression in human colon cancer. Clinical Cancer Res Off J Am Assoc Cancer Res. 2012;18:737–47.CrossRef Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. Mir-1 downregulation cooperates with macc1 in promoting met overexpression in human colon cancer. Clinical Cancer Res Off J Am Assoc Cancer Res. 2012;18:737–47.CrossRef
31.
go back to reference Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, et al. Down-regulation of micro-rna-1 (mir-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by mir-1. J Biol Chem. 2008;283:33394–405.CrossRefPubMedPubMedCentral Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, et al. Down-regulation of micro-rna-1 (mir-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by mir-1. J Biol Chem. 2008;283:33394–405.CrossRefPubMedPubMedCentral
32.
go back to reference Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, et al. Microrna-1/206 targets c-met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009;284:29596–604.CrossRefPubMedPubMedCentral Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, et al. Microrna-1/206 targets c-met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009;284:29596–604.CrossRefPubMedPubMedCentral
Metadata
Title
Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1
Authors
Kewei Zhu
Wanchun Wang
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4187-3

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine